Dupixent showed significant and clinically meaningful improvements in both esophageal distensibility as well as disease-related structural ...
After losing the top spot in March to Johnson & Johnson’s immunology drug Tremfya, AbbVie’s rival med Skyrizi is back as the ...
Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD) expected later this year:- APEX Phase 2 ...
NKTR looks de-risked after positive Rezpeg phase 2 data in atopic dermatitis & alopecia areata, with 80% upside and $1.1B ...
Sanofi SA (SNY) reports robust Q1 2026 performance with significant sales growth and strategic advancements in key product lines.
Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin ...
Earnings call Sanofi delivered a robust Q1 2026 with net sales up 13.6% to EUR 10.5 billion and business EPS up 14% YoY, driven by strong performance in Dupixent, new launches, and recent acquisitions ...
We were pleased with Regeneron's performance to start 2026, highlighted by strong commercial execution across our key growth products, continued pipeline progress, a disciplined approach to capital ...
French drugmaker Sanofi SA SNY and its partner Regeneron Pharmaceuticals Inc. REGN on Wednesday secured U.S. Food and Drug ...
In this episode, the panel considers safety questions surrounding OX40-targeted therapy in light of the Kaposi sarcoma (KS) ...
Discussions at the American Academy of Dermatology annual meeting highlighted a rapidly evolving treatment landscape for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results